Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Non-Small-Cell Lung 78Lung Neoplasms 44Carcinoma, Hepatocellular 42Small Cell Lung Carcinoma 28Breast Neoplasms 18Cholangiocarcinoma 17Urinary Bladder Neoplasms 16Biliary Tract Neoplasms 15Liver Neoplasms 13Neoplasms 12Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 11Ovarian Neoplasms 9Carcinoma 9Squamous Cell Carcinoma of Head and Neck 8Endometrial Neoplasms 7Colorectal Neoplasms 7Stomach Neoplasms 6Carcinoma, Transitional Cell 6Melanoma 5Gallbladder Neoplasms 5Esophageal Neoplasms 5Carcinoma, Renal Cell 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Neoplasms by Site 4Mesothelioma 4

Interventions

Gemcitabine 16Mitomycin 10Docetaxel 6BCG Vaccine 6erdafitinib 5durvalumab 4dodecyl maltoside 4Cystoscopy 4ALT-803 4Radiotherapy 25-aminolevulinic acid hexyl ester 2viscum album peptide 1tremelimumab 1toripalimab 1pirarubicin 1pemigatinib 1monalizumab 1hydroxycamptothecinum 1enfortumab vedotin 1chondroitin sulfate, sodium hyaluronate drug combination 1bicalutamide 1Watchful Waiting 1Urine Specimen Collection 1Transurethral Resection of Bladder 1Surveys and Questionnaires 1Patient Discharge 1Paclitaxel 1Nonsteroidal Anti-Androgens 1Mitozytrex 1Maintenance 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Non-Muscle Invasive Bladder Neoplasms × durvalumab × 1 year × Clear all
NCT05943106 2026-05-26

PATAPSCO

AstraZeneca

Phase 3 Active not recruiting
100 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT03317158 2026-04-15

ADAPT-BLADDER

Hoosier Cancer Research Network

Phase 1/2 Recruiting
55 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03528694 2026-04-14

POTOMAC

AstraZeneca

Phase 3 Active not recruiting
1,018 enrolled 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06503614 2026-04-08

ENHANCE

Hoosier Cancer Research Network

Phase 2 Recruiting
60 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡